1. Scrip
  2. >>R&D

IIL-Griffith Univ Readying Reasonably Priced COVID-19 Vaccine

Vaccine Launch Expected In 18-24 Months

 
• By Vibha Ravi

The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.

Independent
IIL-Griffith May Disrupt COVID-19 Vaccines Pricing • Source: Shutterstock

Indian Immunologicals Ltd has tied up with Australia’s Griffith University to develop a COVID-19 vaccine. While this by itself might not draw much attention given that nearly 60 vaccines are currently in the works to tackle the disease caused by the SARS-CoV-2 virus, the partnership’s capacity to disrupt potential pricing is noteworthy.

State-owned Indian Immunologicals Ltd (IIL) is one of India’s leading companies in human and veterinary biologicals and is known to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

S&E In Brief: Launch Updates And Political Headwinds

 
• By Sushmita Panda

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By Aakash Babu

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.